Role of melatonin in mood disorders and the antidepressant effects of agomelatine

Bibliography

• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990 – 2020: global burden of disease study. Lancet 1997;349:1498–504
   PubMed Web of Science ®Google Scholar
• Lopez AD, Mathers CD, Ezzati M, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57
   PubMed Web of Science ®Google Scholar
• Mykletun A, Bjerkeset O, Dewey M, Anxiety, depression, and cause –specific mortality: the HUNT study. Psychosom Med 2007;69(4):323-31
   PubMed Web of Science ®Google Scholar
• Mykletun A, Bjekeset O, Overland S, Levels of anxiety and depression as predictors of mortality: the HUNT study. Br J Psychiatry 2009;195(2):118-25
   PubMed Web of Science ®Google Scholar
• Testa G, Cacciatore F, Galizia G, Depressive symptoms predict mortality in elderly subjects with chronic heart failure. Eur J Clin Invest 2011;41(12):1310-17
   PubMed Web of Science ®Google Scholar
• Markkula N, Harkanen T, Perala J, Mortality in people with depressive, anxiety and alcohol use disorders in Finland. Br J Psychiatry 2012;200:143-9
   PubMed Web of Science ®Google Scholar
• Patten SB, Williams JV, Lavorato D, Mortality associated with major depression in a Canadian community cohort. Can J Psychiatry 2011;56:658-66
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause, 1990 – 2020: global burden of disease study. Lancet 1997;349:1498-504
   PubMed Web of Science ®Google Scholar
• Celada P, Puig M, Amasrgos-Bosch M, The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252-65
   PubMed Web of Science ®Google Scholar
• Sen S, Sanacora G. Major depression: emerging therapeutics. Mt Sinai J Med 2008;75:204-25
   PubMed Web of Science ®Google Scholar
• Nestler EJ, Barrot M, De Leone RJ, Neurobiology of depression. Neuron 2002;34:13-25
   PubMed Web of Science ®Google Scholar
• Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol 2008;23:571-85
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Trakht I, Pathophysiology of depression: role of sleep and the melatonergic system. Psychiat Res 2009;201-14
   PubMed Web of Science ®Google Scholar
• Riemann D, Berger M, Voderholzer U. Sleep and depression: results from psycho- biological studies. Biol Psychol 2001;57:67-103
   PubMed Web of Science ®Google Scholar
• Roberts RE, Shema SJ, Kaplan GA, Sleep complaints and depression in an aging cohort: a prospective perspective. Am J Psychiatry 2000;157:81-8
   PubMed Web of Science ®Google Scholar
• Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves and sleep spindle activity in humans. J Neurosci 1995;15:3526-38
   PubMed Web of Science ®Google Scholar
• Lustberg L, Reynolds CE. Depression and insomnia: questions of cause and effect. Sleep Med Rev 2000;4:253-62
   PubMed Web of Science ®Google Scholar
• Moore RY, Klein DC. Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity. Brain Res 1974;71:17-33
   PubMed Web of Science ®Google Scholar
• Sadun AA, Schaechter JD, Smith LE. A retino hyothalamic pathway in man: light mediation of circadian rhythms. Brain Res 1984;302:371-7
   PubMed Web of Science ®Google Scholar
• Kripke DF, Mullaney DJ, Atkinson M, Circadian rhythm disorders in manic- depressives. Biol Psychiatry 1978;13:335-51
   PubMed Web of Science ®Google Scholar
• Kripke DF, Risch SC, Janowsky D. Bright white light alleviates depression. Psychiat Res 1983;10:105-12
   PubMed Web of Science ®Google Scholar
• Wetterberg L. Melatonin in adult depression. In: Shafii M, Shafii SL. editors Melatonin in psychiatric and neoplastic disorders. American Psychiatry Press; Washington DC: 1998. p. 43-79
   Google Scholar
• Lewy AJ, Sack RL, Cutler NL, Melatonin in circadian phase sleep and mood disorders. In: Shafii M, Shafii SL. editors Melatonin in psychiatric and neoplastic disorders. American Psychiatry Press; Washington DC: 1998. p. 81-104
   Google Scholar
• Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137-51
   PubMed Web of Science ®Google Scholar
• Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994;13:1177-85
   PubMed Web of Science ®Google Scholar
• Reppert SM, Godson C, Mahle CD, Molecular characterization of a second melatonin receptor expressed in human retina and brain: the MelIb melatonin receptor. Proc Natl Acad Sci USA 1995;92:8734-8
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Cardinali DP, Delagrange P, Melatonin receptors. In: IUPHAR, editor The IUPHAR compendium of receptor characterization and classification. 2nd edition. IUPHAR Media; 2000. p. 271-7
   Google Scholar
• Liu C, Weaver DR, Jin X, Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997;19:91-102
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Trakht I, Srinivasan V, Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Progr Neurobiol 2008;88:264-71
   Google Scholar
• Morgan PJ, Barrett P, Howell HE, Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 1994;8:101-46
   Google Scholar
• Bouton JA, Audinot V, Ferry G, Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci 2005;26:412-19
   PubMed Web of Science ®Google Scholar
• Brydon L, Roka F, Petit L, Dual signalling of human mel1a melatonin receptors via Gi2 and Gq/11 proteins. Mol Endocrinol 1999;13:2025-38
   PubMed Web of Science ®Google Scholar
• Sampson SR, Lupowitz Z, Braiman L, Role of protein kinase C alpha in melatonin signal transduction. Mol Cell Endocrinol 2006;252:82-7
   PubMed Web of Science ®Google Scholar
• Rivera-Bermudez MA, Gerdin MJ, Earnest DJ, Regulation of basal rhythmicity in protein kinase C activity by melatonin in immortalized rat suprachiasmatic nucleus cells. Neurosci Lett 2003;346:37-40
   PubMed Web of Science ®Google Scholar
• Benitez–King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006;40:1-9
   PubMed Web of Science ®Google Scholar
• Wiesenberg I, Missbach M, Kahlen JP, Transcriptional activation of the nuclear receptor RZRα by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acid Res 1995;23:327-33
   PubMed Web of Science ®Google Scholar
• Wirz-Justice A, Arendt J. Diurnal, menstrual cycle and seasonal indole rhythms in man and their modifications in affective disorders. In: Obiols J, Ballus C, Gonzales Monclyus E, editors Biological psychiatry today. Elsevier North-Holland; Amsterdam: 1979. p. 294-302
   Google Scholar
• Wetterberg L. Clinical importance of melatonin. Progr Brain Res 1979;52:539-47
   PubMedGoogle Scholar
• Mendlewicz J, Linkowski P, Branchey L, Abnormal 24 hour pattern of melatonin secretion in depression. Lancet 1979;2:1362
   PubMed Web of Science ®Google Scholar
• Beck-Friis J, Hanssen T, Kjellman BF, Serum melatonin and cortisol in human subjects after the administration of dexamethasone and propranolol. Psychopharmacol Bull 1979;19:646-8
   Google Scholar
• Beck-Friis J, Kjellman BF, Aperia B, Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of low melatonin syndrome. Acta Psychiatr Scand 1985;71:319-30
   PubMed Web of Science ®Google Scholar
• Beck-Friis J, von Rosen D, Kjellman BF, Melatonin in relation to body measures, sex, age, season and the use of drugs in patients with major affective disorders and healthy subjects. Psychoneuroendocrinology 1984;9:261-77
   PubMed Web of Science ®Google Scholar
• Carrol BJ. The dexamethasone suppression test for melancholia. Br J Psychiatry 1982;140:292-304
   PubMed Web of Science ®Google Scholar
• Nair NP, Hariharasubramanian N, Pilapil C, Circadian rhythm of plasma melatonin in endogenous depression. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:715-18
   PubMed Web of Science ®Google Scholar
• Wehr TA, Sack DA, Duncan WC, Sleep and circadian rhythms in affective patients isolated from external time cues. Psychiatry Res 1985;15:327-39
   PubMed Web of Science ®Google Scholar
• Tuunainen A, Kripke DF, Elliott JA, Depression and endogenous melatonin in postmenopausal women. J Affect Disord 2002;69:149-58
   PubMed Web of Science ®Google Scholar
• Sekula LK, Lucke JF, Heist EK, Neuroendocrine aspects of primary endogenous depression. XV: mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiatry Res 1997;69:143-53
   PubMed Web of Science ®Google Scholar
• Golden RN, Markey SP, Risby ED, Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin out put. Arch Gen Psychiatry 1988;45:150-4
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Smits M, Spence W, Melatonin mood disorders. World J Psychiatry 2006;7:138-51
   Google Scholar
• Arendt J. Melatonin: a new probe in psychiatric investigation ? Br J Psychiatry 1989;155:585-90
   PubMed Web of Science ®Google Scholar
• Rubin RT, Heist EK, McGeoy SS, Neuroendocrine aspects of primary endogenous depression. XI Serum melatonin measures in patients and matched control subjects. Arch Gen Psychiatry 1992;558-67
   PubMed Web of Science ®Google Scholar
• Shafii M, MacMillan DR, Key MP, Case Study : melatonin in severe obesity. J Am Acad Child Adoles Psychiatry 1997;36:412-16
   PubMed Web of Science ®Google Scholar
• Crasson M, Kjiri S, Colin A, Serum melatonin and urinary 6-sulfatoxy - melatonin in major depression. Psychoneuroendocrinology 2004;29:1-12
   PubMed Web of Science ®Google Scholar
• Thompson C, Mezey G, Corn T, The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects. Br J Psychiatry 1985;147:389-93
   PubMed Web of Science ®Google Scholar
• Venkoba rao A, Parvathi Devi S, Srinivasan V. Urinary melatonin in depression. Ind J Psychiatry 1983;25:167-72
   PubMedGoogle Scholar
• Sack RL, Lewy AJ. Desmethylimipramine treatment increases melatonin production in humans. Biol Psychiatry 1986;21:406-10
   PubMed Web of Science ®Google Scholar
• Bunney WE Jr, Murphy DL, Goodwin FK, The Switch process from depression to mania. Relationship to drugs which alter brain monoamines. Lancet 1970;1:1022-7
   PubMed Web of Science ®Google Scholar
• Sitaram N, Gillin JC, Bunney WE Jr. The Switch process in manic-depressive illness. Circadian variations in time of switch and sleep and manic ratings before and after switch. Acta psychiatr Scand 1978;58:267-78
   PubMed Web of Science ®Google Scholar
• Wehr TA, Goodwin FK. Tricycles modulate frequency of mood cycles. Chronobiologia 1979;6:377-85
   PubMedGoogle Scholar
• Souetre E, Salvati E, Belugou JL, Circadian rhythms in depression and recovery: evidence for blunted amplitude in the main chronobiological abnormality. Psychiatry Res 1989;28:263-78
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Tighe S, McVey G, Melatonin and Cortisol “switches” during mania, depression and euthymia in a drug free bipolar patient. J Nerv Ment Dis 1989;177:300-3
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Kutcher SP, Ralevski E, Nocturnal melatonin and 24 hr 6-sulfatoxymelatonin levels in various phases of bipolar disorder. Psychiatry Res 1996;63:219-22
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Wehr T, Gold PW, Plasma melatonin in manic depressive illness. In: . Kopin . Barchas Usdin EIJJD. editors Catecholamines: basic and clinical frontiers. Volume 2 Pergamon Press; Oxford: 1979. p. 1173-5
   Google Scholar
• Nurnberger JI Jr, Adkins S, Lahiri DK, Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch Gen Psychiatry 2000;57:572-9
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Sack RL, Singer CM, Winter Depression and phase shift hypothesis for bright light's therapeutic effects: history, theory and experimental evidence. J Biol Rhythms 1988;3:121-34
   PubMed Web of Science ®Google Scholar
• Danilenko KV, Putilov AA, Russkikh GS, Diurnal and seasonal variations of melatonin and serotonin in women with seasonal affective disorder. Arctic Med Res 1994;53:137-45
   PubMedGoogle Scholar
• Wehr TA, Duncan WC Jr, Sher L, A circadian signal of change of season in patients with seasonal affective disorders. Arch Gen Psychiatry 2001;58:1108-14
   PubMed Web of Science ®Google Scholar
• Touitou Y, Fevre M, Bogden A, Patterns of plasma melatonin with ageing and mental condition: stability of nyctohemeral rhythms and differences in seasonal variations. Acta Endocrinol (Copenh) 1984;106:145-51
   PubMedGoogle Scholar
• Kivela A, Kauppila A, Ylostalo O, Seasonal, menstrual and circadian secretions of melatonin, gonadotrophins and prolactin in women. Acta Physiol Scand 1988;132:321-7
   PubMedGoogle Scholar
• Honma K, Honma S, Kohsaka M, Seasonal variation in the human circadian rhythm: dissociation between sleep and temperature rhythms. Am J Physiol 1992;262:R885-91
   PubMed Web of Science ®Google Scholar
• Morera AL, Abreu P. Seasonality of psychopathology and circannual melatonin rhythms. J Pineal Res 2006;41:279-83
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Bauer VK, Cutler NL, Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 1988;55:890-6
   Web of Science ®Google Scholar
• Terman JS, Terman JS. Light therapy for seasonal and non seasonal depression: protocol, safety and side effects. CNS Spectr 2005;10:647-63
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007;12:331-59
   PubMed Web of Science ®Google Scholar
• Rakofsky JJ, Holtzheimer PE, Nemeroff CB. Emerging targets for antidepressant therapies. Curr Opin Chem Biol 2009;13:291-302
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Trakht I, Srinivasan V, The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J Biol Psychiatry 2008;4:1-13
   Google Scholar
• Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep 2006;8:478-88
   PubMedGoogle Scholar
• Winokur A, Gary KA, Rodner S, Depression, sleep physiology and antidepressant drugs. Depress Anxiety 2001;14:19-28
   PubMed Web of Science ®Google Scholar
• De Martinis NA, Winokur A. Effects of psychiatric medications on sleep and sleep disorders. CNS Neurol Disord Drug Targets 2007;6:17-29
   PubMedGoogle Scholar
• Racagni G, Riva MA, Molteni R, Mode of action of agomelatine : synergy between melatonergic and 5-HT2c receptors. World J Biol Psychiatry 2011;12:574-87
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Targum SD, Tandon R, Defining and measuring clinical effective- ness in the treatment of schizophrenia. Psychiatry Serv 2005;56(3):273-82
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Young AH, Blier P. Strategies to achieve clinical effectiveness: refining existent therapies and pursuing emerging targets. J Affect Disord 2011
   Web of Science ®Google Scholar
• Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011;21:S703-9
   PubMed Web of Science ®Google Scholar
• Serna MC, Cruz I, Real J, Duration and adherence of antidepressant treatment. (2003 to 2007) based on prescription database. Eur Psychiatry 2010;25(4):206-13
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Keene MS, Eaddy M, Differences in medication adherence and health care resource utilization patterns: older versus newer antidepressants agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22(11):963-73
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, The novel melatonin agonist (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of fronocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
   PubMed Web of Science ®Google Scholar
• Bourin M, Mocaer E, Porsolt R. Antidepressant like activity of S 20098 (agomelatine) in the forced swimming test in rodents.: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004;29:126-33
   PubMed Web of Science ®Google Scholar
• Fuchs E. Social stress in tree shrews as an animal model of depression: an example of behavioural model of CNS disorder. CNS Spectr 2005;10:182-90
   PubMed Web of Science ®Google Scholar
• Pepin MC, Pothier F, Barden N. Antidepressant drug action in a transgenic mouse model of endocrine changes seen in depression. Mol Pharmacol 1992;42:991-5
   PubMed Web of Science ®Google Scholar
• Barden N, Shink E, Labbe M, Antidepressant action of agomelatine (S20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:908-16
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca B, Boyer PA, Effect of agomelatine in the chronic mild stress model of depression. Neuropsychopharmacology 2003;28:694-703
   PubMed Web of Science ®Google Scholar
• Redman JR, Guardiola-Lemaitre B, Brown M, Dose dependent effects of S-20098, a melatonin agonist on a direction of re-entrainment of rat circadian activity rhythms. Psychopharmacol (Berlin) 1995;118:385-90
   PubMed Web of Science ®Google Scholar
• Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Successful use of S-20098 and melatonin in an animal model of delayed-sleep phase syndrome (DSPS). Pharmacol Biochem Behav 1993;46:45-9
   PubMed Web of Science ®Google Scholar
• Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist is dose and plasma concentration. Dependent. Pharmacol Biochem Behav 1996;54:713-18
   PubMed Web of Science ®Google Scholar
• Redman JR, Francis AJ. Entrainment of rat circadian rhythms by melatonin antagonist S-20098 requires the intact suprachiasmatic nucleus but not pineal. J Biol Rhythms 1998;13:39-51
   PubMed Web of Science ®Google Scholar
• Pitrosky B, Kirsch R, Malan A, Organization of rat circadian rhythms during daily infusion of melatonin or S 20098, a melatonin agonist. Am J Physiol 1999;277(3 Pt 2):R812-28
   Google Scholar
• Weibel L, Turek FW, Mocaer E, A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light- dark cycle. Brain Res 2000;880(1-2):207-11
   PubMed Web of Science ®Google Scholar
• Rainer Q, Xia L, Guilloux JP, Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol 2011; doi:10.1017/S 1461145711000356
   PubMed Web of Science ®Google Scholar
• Paizanis E, Renoir T, Lelievre V, Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor –impaired mice. Int J Neuropsychopharmacol 2010;13:759-74
   PubMed Web of Science ®Google Scholar
• Bansar M, Soumier A, Hery M, Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006;59:1087-96
   PubMed Web of Science ®Google Scholar
• Soumier A, Bansar M, Lortet S, Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009;34:2390-403
   PubMed Web of Science ®Google Scholar
• Bannerman DM, Deacon RM, Brady S, A comparison of GluR-A deficient and Wild type mice on a test battery assessing sensorimotor, affective and cognitive behaviours. Behav Neurosci 2004;118:643-7
   PubMed Web of Science ®Google Scholar
• Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 2010;65:7-19
   PubMed Web of Science ®Google Scholar
• Alves SH, Pinheiro G, Motta A, Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but not dorsal hippocampus. Behav Pharmacol 2004;15:37-43
   PubMed Web of Science ®Google Scholar
• ; US National Institute of Health. Available from: http:/www.clinicaltrials. govt/show/NCT00461242/term= agomelatine =1
   Google Scholar
• Papp M, Gruca P, Boyer P, Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003;28:604-703
   Google Scholar
• San L, Arranz B. A novel mechanism of antidepressant action involving melatonergic serotonergic system. Eur Psychiatry 2008;23:396-402
   PubMed Web of Science ®Google Scholar
• Masana MJ, Benlousif S, Dubocovich ML. Circadian rhythm of MT1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J Pineal Res 2000;28:185-92
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Rivet JM, Mirtazapine enhances frontocortical dopaminergic and cortico limbic adrenergic but not serotonergic transmission by blockade of alpha-2 adrenergic and serotonergic 2c receptors; a comparison with citalopram. Eur J Neurosci 2000;12:1079-95
   PubMed Web of Science ®Google Scholar
• Mairesse J, Silletti V, Laloux C, Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats. Int J Neuropsychopharmacol 2012;6:1-16
   Google Scholar
• Racagni G, Riva MA, Popoli M. The interactions between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol 2007;22(Suppl 2):S9-S14
   Google Scholar
• Martin JR, Bos M, Jenck F, 5-HT2c receptor agonists : pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998;286:913-24
   PubMed Web of Science ®Google Scholar
• Fuchs E, Simon M, Schmelting Pharmacology of a new antidepressant; benefits of the implications of the melatonergic system. Int J Clin Psychopharmacol 2006(Suppl 1):S17-20
   Google Scholar
• Krauchi K, Cajochen C, Mori D, Early evening melatonin and S 20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997;272:R1178-88
   PubMed Web of Science ®Google Scholar
• Leproult R, Van Onderbergen A, L'Hermite-Balerlaux M, Phase shifts of 24 –h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy old men. Clin Endocrinol 2005;63:296-304
   Google Scholar
• Eser D, Baghai TC, Moller HJ. Agomelatine: the evidence for its place in the treatment of depression. Core Evid 2009;3:171-9
   Google Scholar
• Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist in the treatment of major depressive disorder. Int Clin Psychopharmacol 2002;17:239-47
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley RA. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16(2):93-100
   PubMed Web of Science ®Google Scholar
• Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2c antagonistic properties in major depressive disorder. Int J Neuropsychol Pharmacol 2007;10(5):661-73
   PubMed Web of Science ®Google Scholar
• Lemoine R, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine: randomized, double- blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Konstantinidis A, Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl) 2007;190:575-9
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S, Fulton K, A double blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28(3):329-33
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine Bipolar study group. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007;6:628-35
   Google Scholar
• Goodwin GM, Emsley R, Rembry S, Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24–week randomized, double-blind, placebo controlled trial. J Clin Psychiatry 2009;70(8):1128-37
   PubMed Web of Science ®Google Scholar
• Zajecka J, Schatzberg A, Stahl Efficacy and safety of agomelatine in treatment of major depressive disorder: a multicenter, randomized, double- blind, placebo controlled trial. J Clin Psychopharmacol 2010;30(2):135-44
   PubMed Web of Science ®Google Scholar
• Stahl SM, Fava M, Trivedi MH, Agomelatine in the treatment of major depressive disorder: an 8 week, multicenter, randomized, placebo controlled trial. J Clin Psychiatry 2010;71(5):616-26
   PubMed Web of Science ®Google Scholar
• Hale A, Corral RM, Mencacci C, Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized double-blind study. Int Clin Psychopharmacol 2010;25(6):305-14
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G, Wulff K, Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double blind comparison with sertraline. J Clin Psychiatry 2010;71(2):109-20
   PubMed Web of Science ®Google Scholar
• Di Giannantonio M, Di Iorio G, Guglielmo R, Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents 2011;25(1):109-14
   PubMed Web of Science ®Google Scholar
• De Beradis D, Serroni N, Campanella D, A case of Obsessive-compulsive disorder successfully treated with agomelatine monotherapy. J Clin Psychopharmacol 2012;32(2):289-90
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S. Severe depression and antidepressants : focus on a pooled analysis of placebo –controlled studies on agomelatine. Int Clin Psychoharmacol 2007;22:283-91
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Ashberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 2006;21(Suppl 1):531-5
   Google Scholar
• Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010;24(6):479-99
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kennedy SH, Burrows GD, Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation with paroxetine. A randomized double-blind placebo controlled discontinuation study. Int Clin Psychopharmacol 2004;19:271-80
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Srinivasan V, Cardinali DP, Could agomelatine be the ideal antidepressant ?. Expert Rev Neurother 2006;6:1595-608
   PubMedGoogle Scholar
• Fornaro M, Prestia D, Colicchio S, A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010;8:287-304
   PubMed Web of Science ®Google Scholar
• De Beradis D, Di Lorio G, Acciavatti T, The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011;10(1):119-32
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Hajak G, Montplaisir J, Comparison of agomelatine and escitalopram on night time sleep and daytime condition and efficiency in major depressive disorder patients. Int Clin Psychopharmacol 2011;26:252-62
   PubMed Web of Science ®Google Scholar
• Stein Ahokas AA, deBodinat C. Efficacy of agomelatine in generalized anxiety disorder.: a randomized double-blind placebo controlled study. J Clin Psychopharmacol 2008;28:561-6
   PubMed Web of Science ®Google Scholar
• Crippa JAS, Hallak JEC, Zuardi AW, Agomelatine in the treatment of social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1357-8
   PubMed Web of Science ®Google Scholar
• Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 2006;21(Suppl 1):S25-9
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo–controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22:283-91
   PubMed Web of Science ®Google Scholar
• Green B. Focus on agomelatine. Curr Med Res Opin 2011;27(4):745-9
   PubMed Web of Science ®Google Scholar
• Bertaina-Anglade V, La Rochelle CD, Boyer PA, Antidepressant like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 2006;17:703-13
   PubMed Web of Science ®Google Scholar